Nassar, Amin H.

Distribution of KRAS G12C Somatic Mutations across Race, Sex, and Cancer Type

Nassar, A. H., Adib, E., & Kwiatkowski, D. J. (2021) · New England Journal of Medicine

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 210

Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors

Nassar, A. H., Adib, E., Abou Alaiwi, S., El Zarif, T., Groha, S., Akl, E. W., Nuzzo, P. V., Mouhieddine, T. H., Perea-Chamblee, T., Taraszka, K., et al. (2022) · Cancer Cell

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 121

Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs).

Pier Vitale, N., Pond, G. R., Abou Alaiwi, S., Nassar, A., Flippot, R., Choueiri, T. K., Harshman, L. C., & Sonpavde, G. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 4